WorldPharmaNews
  • Home
  • Business
  • Research
  • Jobs
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions 02 December 2019
Mylan and Pfizer announce Viatris as the new company name in the planned Mylan-Upjohn combination 13 November 2019
OPKO and Pfizer announce positive Phase 3 top-line results for somatrogon 24 October 2019
Akcea and Pfizer Inc. announce licensing agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx 07 October 2019
Ian Read to retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla named Chairman 30 September 2019
Pfizer invests half billion dollars to advance state-of-the-art gene therapy facility in Sanford, North Carolina 29 August 2019
The Pfizer Foundation invests in 20 organizations tackling infectious diseases and antimicrobial resistance 21 August 2019
Mylan and Upjohn, a division of Pfizer, to combine, creating a new champion for global health uniquely positioned to fulfill the world's need for medicine 29 July 2019
Pfizer completes acquisition of Therachon 05 July 2019
Jeff Settleman, Ph.D., joins Pfizer to lead Oncology Research & Development 07 June 2019
Pfizer announces top-line results from Phase 3 Trial of LYRICA® (pregabalin) in primary generalized tonic-clonic seizures 24 May 2019
Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis 22 April 2019
Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics 21 March 2019
Ochsner Health System and Pfizer partner to develop innovative models for clinical trials 19 February 2019
The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients 08 February 2019
Pfizer receives positive CHMP opinion for Vizimpro® (dacomitinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations 01 February 2019
Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain 29 January 2019
US FDA accepts regulatory submissions for review of tafamidis to treat transthyretin amyloid cardiomyopathy 14 January 2019
Pfizer initiates phase 2b/3 clinical trial for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with moderate to severe alopecia areata 05 January 2019
Pfizer receives positive CHMP opinion for oncology biosimilar, ZIRABEV™ (bevacizumab) 14 December 2018
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
  • AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
  • FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions
  • Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
  • Bayer selects Pharmaron as partner organization

Research & Development

  • The gut may be involved in the development of multiple sclerosis
  • Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer
  • Investigational drugs reduce risk of death from Ebola virus disease
  • Pharmacist-led interventions may help prevent cardiovascular disease
  • A protein tag to study the immune system
  • Industry executives: Profits drive rising prices for MS drugs
  • Artificial Intelligence algorithm can learn the laws of quantum mechanics and speed up drug delivery

Conferences & Events

  • Excellent market conditions at largest ever CPhI Worldwide bodes well for global pharma in 2020
  • SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020
  • SMi's 4th Annual 3D Cell Culture
  • Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
  • RNA Therapeutics Conference and Focus Day
  • CPhI Worldwide announces the winners of the 16th Pharma Awards
  • CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023

Regulatory Affairs

  • FDA approves first generics of Gilenya
  • FDA approves novel treatment to target abnormality in sickle cell disease
  • FDA approves first treatment for inherited rare disease
  • FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
  • FDA approves first therapy to treat patients with rare blood disorder
  1. You are here:  
  2. Home
  3. Pfizer
  4. FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2006 - 2017. All Rights Reserved. WORLD PHARMA JOBS | PharmaNews.eu | eHealthNews.eu | (HEALTH IT) SPACE